Neuren Pharmaceuticals (ASX:NEU) has approved the issue of new 2.16 million share options as a long-term incentive at an exercise price of AU$12.91, according to a Friday Australian bourse filing.
The issue follows its meeting with the US Food and Drug Administration for Phelan-McDermid syndrome, a neurodevelopmental disorder for which it's developing its drug candidate NNZ-2591.
The exercise price is equal to the volume-weighted average price of trading during the five days before the issue, and the options expire five years after the issue.
Out of the total, 360,000 options for Chief Executive Officer Jon Pilcher will be subject to shareholder approval and will not be issued before receiving said approval at a future meeting.
The company will vest one-third of the options upon each of the following milestones: completion of last patient dosing in a Phase 3 trial, acceptance for filing of a marketing application or completion of a major partnership deal, and first patient dosing in a pivotal trial for a second indication.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。